Improving Patient Outcomes in Glaucoma: New Drug Delivery Systems, New MIGS (CME Webcast)
Provision of safe and efficacious treatments for patients with glaucoma who are challenged to adhere to topical treatment regimens or who need additional interventions when first-line options fail is an important unmet need. Both sustained drug delivery devices and minimally invasive glaucoma surgery (MIGS) techniques strive to meet that need. Several sustained drug delivery devices are currently under investigation, with some devices demonstrating encouraging results. Approved and investigational subconjunctival MIGS have been shown to reduce intraocular pressure substantially for most patients while relieving drop burden. Common side effects include postoperative needling, nonpersistent loss of best-corrected visual acuity, and transient hypotony. Several preoperative and perioperative strategies contribute to surgical success. This webcast captures a live CME symposium held during the 2020 Annual Meeting of the American Glaucoma Society. The desired results of this educational activity are for learners to improve their knowledge and competence regarding the potential role of sustained drug delivery systems and newer MIGS in improving visual outcomes for patients with glaucoma who are challenged to adhere to topical therapy.
This educational activity is intended for ophthalmologists caring for patients with glaucoma.
Upon completion of this activity, participants will be better able to:
- Review the pharmacodynamics, efficacy, and safety of sustained drug delivery devices for glaucoma therapy
- Select patients most likely to benefit from sustained drug delivery systems for glaucoma
- Apply evidence to select patients for subconjunctival MIGS procedures
- Describe methods to optimize success of bleb-based MIGS
|Joseph F. Panarelli, MD (Chair)|
Associate Professor of Ophthalmology
Chief, Division of Glaucoma Services
Glaucoma Fellowship Director
NYU Langone Eye Center
New York, New York
|Jonathan S. Myers, MD|
Director, Glaucoma Service
Wills Eye Hospital
Associate Professor of Ophthalmology
Sidney Kimmel Medical College
Thomas Jefferson University
|Oluwatosin (Tosin) U. Smith, MD|
Attending Clinician and Surgeon
Glaucoma Associates of Texas
Associate Professor of Ophthalmology
UT Southwestern Medical Center
Disclosure Policy Statement
It is the policy of New York Eye and Ear Infirmary of Mount Sinai that the faculty and anyone in a position to control activity content disclose any real or apparent conflicts of interest relating to the topics of the educational activity in which they are participating. They are also required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations. New York Eye and Ear Infirmary of Mount Sinai is committed to providing its learners with quality CME activities and related materials that promote improvements in healthcare and not the proprietary interests of a commercial interest and, thus, has established policies and procedures in place that identify and resolve all conflicts of interest prior to the execution or release of its educational activities. Full disclosure of faculty/planners and their commercial relationships, if any, follows.
Jonathan S. Myers, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Aerie Pharmaceuticals, Inc; Allergan; and Glaukos Corporation; Contracted Research:
Aerie Pharmaceuticals, Inc; Allergan; Diopsys, Inc; Glaukos Corporation; and Zeiss; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Aerie Pharmaceuticals, Inc; and Allergan; Ownership Interest (Stock options, or other holdings, excluding diversified mutual funds): Olleyes Inc.
Joseph F. Panarelli, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Aerie Pharmaceuticals, Inc; Allergan; CorneaGen; Glaukos Corporation; and Santen Inc.
Oluwatosin (Tosin) U. Smith, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Aerie Pharmaceuticals, Inc; Allergan; IRIDEX Corporation; and New World Medical, Inc; Contracted Research: Allergan; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Aerie Pharmaceuticals, Inc; Allergan; and Bausch & Lomb Incorporated; Other (Medical Monitor): Glaukos Corporation.
New York Eye and Ear Infirmary of Mount Sinai Peer Review Disclosure
Kateki Vinod, MD, has no relevant commercial relationships to disclose.
Editorial Support Disclosures
Erika Langsfeld, PhD; Cynthia Tornallyay, RD, MBA, CHCP; Kimberly Corbin, CHCP; Barbara Aubel; and Michelle Ong have no relevant commercial relationships to disclose.
The contributing physicians listed above have attested to the following:
- that the relationships/affiliations noted will not bias or otherwise influence their involvement in this activity;
- that practice recommendations given relevant to the companies with whom they have relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and
- that all reasonable clinical alternatives will be discussed when making practice recommendations.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of New York Eye and Ear Infirmary of Mount Sinai and MedEdicus LLC. The New York Eye and Ear Infirmary of Mount Sinai is accredited by the ACCME to provide continuing medical education for physicians.
AMA Credit Designation Statement
The New York Eye and Ear Infirmary of Mount Sinai designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This continuing medical education activity is supported through an unrestricted educational grant from Allergan.
This CME activity includes discussion of unlabeled and/or investigative uses of drugs. Please refer to the official prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.
New York Eye and Ear Infirmary of Mount Sinai Privacy & Confidentiality Policies
CME Provider Contact Information
For questions about this activity, call 212-870-8125.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of New York Eye and Ear Infirmary of Mount Sinai, MedEdicus LLC, or Allergan.
This continuing medical education activity is jointly provided by New York Eye and Ear Infirmary of Mount Sinai and MedEdicus LLC.
This CME activity is copyrighted to MedEdicus LLC ©2020. All rights reserved. 217
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Learning Method and Medium
This educational activity consists of a six (6)-question pretest, a webcast, and five (5) study questions. The participant should, in order, read the learning objectives, complete the pretest, view the webcast, answer all questions in the post test, and complete the evaluation. To receive credit for this activity, please complete the post test and evaluation. This educational activity should take a maximum of 1.0 hour to complete.